Glenmark launches anti-diabetes Remogliflozin in India

Glenmark Pharmaceuticals a research-led global integratedpharmaceutical company, on Monday announced the launch of its novel, patentprotected and globally-researched sodium glucose co-transporter (SGLT2)inhibitor ‘Remogliflozin’ in India.

The drug is indicated in the treatment of type-2 diabetesmellitus in adults, a statement issued by the Glenmark said.

   

Glenmark is the first company in the world to launchRemogliflozin and India is the first country to get access to this innovativedrug. Glenmark has launched Remogliflozin in India under brand names ‘Remo’ and’Remozen’.

SGLT2 inhibitors are novel anti-diabetic drugs that helpachieve glycemic control by acting on the SGLT2 receptors in the proximalconvoluted tubule of the kidney, thereby preventing renal reabsorption ofglucose and promoting excretion of glucose in the urine. Along with providingglycemic control, SGLT2 inhibitors help induce weight loss and reducecardiovascular risks.

Leave a Reply

Your email address will not be published. Required fields are marked *

12 + 3 =